Second-Line Oral Chemotherapy (Lomustine, Cyclophosphamide, Etoposide) Versus Intravenous Therapy (Cyclophosphamide, Doxorubicin, and Vincristine) in Patients With Relapsed Small Cell Lung Cancer: A Randomized Phase II Study of GFPC 0501-Reference-Cited by-同舟云学术

Second-Line Oral Chemotherapy (Lomustine, Cyclophosphamide, Etoposide) Versus Intravenous Therapy (Cyclophosphamide, Doxorubicin, and Vincristine) in Patients With Relapsed Small Cell Lung Cancer: A Randomized Phase II Study of GFPC 0501

Published:2015-03 Issue:2 Volume:16 Page:100-105
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Gervais Radj,Le Caer Hervé,Monnet Isabelle,Falchero Lionel,Baize Nathalie,Olivero Gerard,Thomas Pascal,Berard Henri,Auliac Jean Bernard,Chouaid Christos

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database;Navada;J Clin Oncol,2006

2. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline;Cheng;J Thorac Oncol,2007

3. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross resistant schedule;Groen;J Clin Oncol,1999

4. A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer;Pallis;Lung Cancer,2009

5. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer;Kosmas;J Clin Oncol,2001

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics and outcomes of patients with small cell lung cancer - findings from a New Zealand SACT database;Asia-Pacific Journal of Oncology;2023-02-10

2. A cost‐utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan;Cancer Reports;2021-05-02

3. Probiotic Supplements on Oncology Patients’ Treatment-Related Side Effects: A Systematic Review of Randomized Controlled Trials;International Journal of Environmental Research and Public Health;2021-04-17

4. Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined;Translational Lung Cancer Research;2020-10

5. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial;The Lancet Oncology;2020-09